Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10

23 février 2018

14:46
One of the U.S. Food and Drug Administration's highest priorities is our role in ensuring the safety of the foods that Americans consume. We base our regulatory decisions on robust science so consumers can feel confident about the foods they eat. The...

12:25
Biogen Canada today applauded the recent release of end of study results from CHERISH, the Phase 3 study evaluating SPINRAZAtm (nusinersen) for the treatment of individuals with later-onset spinal muscular atrophy (SMA), in The New England Journal of...

12:25
Biogen Canada applaudit la diffusion des résultats définitifs de l'étude de phase III CHERISH, qui portait sur l'utilisation de SPINRAZAMC (nusinersen) dans le traitement de sujets atteints d'une amyotrophie spinale (AS) à révélation tardive. Les...

08:30
Jazz Pharmaceuticals plc today announced that the first patient has been enrolled in a Phase 2 clinical trial evaluating the efficacy and safety of defibrotide for the prevention of acute Graft-versus-Host-Disease (aGvHD) in adult and pediatric...

08:20
Amgen today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for XGEVA® (denosumab) to cover skeletal-related events in...

08:00
Crysvita est le premier traitement du XLH qui cible la cause sous-jacente de la maladie  Crysvita a été reconnu par l'Agence européenne des médicaments comme étant une contribution exceptionnelle à la santé publique  Kyowa Hakko Kirin Co. Ltd,...

08:00
Vascular Grafts Solutions announced today the interim results from the VEST III study, a post-marketing trial which evaluates the effectiveness of the VEST technology (Venous External SupporT) in treatment of saphenous vein graft (SVG) disease after...

08:00
Crysvita is the First Treatment for XLH that Targets the Underlying Cause of the Disease Crysvita Acknowledged by European Medicines Agency as an Outstanding Contribution to PublicHealth Kyowa Hakko Kirin Co. Ltd, (Kyowa Hakko Kirin), Kyowa...


22 février 2018

20:32
As a mother of three, a blood cancer diagnosis four years ago for 36-year-old Emily Dumler was devastating news. Diagnosed with non-Hodgkin's lymphoma, Dumler wound up undergoing six rounds of outpatient chemotherapy. And while doctors thought the...

19:01
In response to rising healthcare challenges in the UK, the NPL, the UK's National Measurement Institute (NMI), has today announced the launch of MEMPHYS, to address the critical need for early diagnosis and treatment of conditions such as cancer,...

16:55
Tears may hold clues to whether someone has Parkinson's disease, according to a preliminary study released today that will be presented at the American Academy of Neurology's 70th Annual Meeting in Los Angeles, April 21 to 27, 2018. "We believe our...

11:30
IDx, a privately-held AI diagnostics company, today announced that IDx-DR, an AI-based system for the autonomous detection of diabetic retinopathy, met its endpoints in a pivotal FDA trial involving 900 people with diabetes. IDx-DR was developed to...

11:30
EMD Serono, Canada, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, and Pfizer Canada Inc. announced that Health Canada has approved BAVENCIOtm (avelumab for injection) for the treatment of metastatic Merkel...

11:30
EMD Serono Canada (entreprise biopharmaceutique présente aux États-Unis et au Canada, et filiale de Merck KGaA, Darmstadt, Allemagne) et Pfizer Canada inc. annoncent que Santé Canada a approuvé BAVENCIOMC (avélumab pour injection) pour le traitement...

11:13
MYR Pharma GmbH today announced the completion of the 48-week-long active treatment phase in MYR 203 clinical trial, a part of Phase 2b program investigating Myrcludex B in combination with pegylated interferon (PEG INF) in chronic hepatitis Delta...

10:30
PLENVU® is the first 1 Litre PEG preparation bowel preparation to demonstrate higher cleansing efficacy than MOVIPREP® (2 Litre PEG + Ascorbate)  Norgine B.V. today announced positive new PLENVU® (NER1006) superiority data at the meeting of...

10:30
PLENVU® est la première préparation intestinale d'un litre à base de PEG à démontrer une efficacité nettoyante supérieure à MOVIPREP® (préparation de 2 litres à base de PEG et d'ascorbate)  Norgine B.V. a annoncé aujourd'hui de nouvelles données...

10:00
The brightest minds in Alzheimer's research are meeting in Las Vegas for the Global Alzheimer's Platform Foundation's GAP-Net Site Optimization Conference from Feb 21 ? 23. GAP-Net is a first-of-its-kind network of clinical trial sites...

09:48
The Center for Medicare and Medicaid Innovation (CMMI) released a new study this week that showed that its chronic care management (CCM) program is associated with lower growth in Medicare costs, an enhanced ability to connect patients with...

09:30
With the popularity of video games and competitive gaming on the rise, players are always looking for an edge. Whether battling a computer opponent or Player Two, one secret weapon can help land the high score: the American Optometric Association's...

08:00
JHL Biotech Inc. announced that the European authority, Bulgarian Drug Agency, has approved a Phase I Clinical Trial Application for a proposed bevacizumab biosimilar, JHL1149. JHL will conduct a three-arm...

08:00
A cancer diagnosis is no longer the death sentence it once was due to many cutting-edge treatments and innovations underway. That is even more encouraging news for the estimated 38.5 percent of men and who will be diagnosed with cancer at some point...

08:00
Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the first patient has been dosed in a Phase...

08:00
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the first patient has been dosed in a phase 1 study assessing the safety and tolerability of DS-1062, an investigational TROP2-targeting antibody drug conjugate (ADC), in...

07:30
Cambridge research facility will advance BenevolentAI drug programmes into the clinic more quickly and at a much larger scale  BenevolentAI, one of the world's largest private AI companies, today announced that it has acquired a state-of-the-art...

07:00
Global Health Solutions, LLC, has announced successful in-vitro and in-vivo data for OV-02, a unique biocidal ointment intended to treat and prevent ocular colonization of viruses, such as those that lead to shingles of the eye and pink eye. OV-02 is...

02:30
Acquisition creates first AI company capable of covering entire drug development process from drug discovery to clinical development  Cambridge research facility will advance BenevolentAI drug programmes into the clinic more quickly and at a much...


21 février 2018

19:48
Imagion Biosystems Limited (ASX:IBX) (Imagion or the Company), a company dedicated to improving healthcare through earlier detection of cancer, announces the appointment of Farideh Bischoff, PhD, as Vice President of Clinical Research. Dr Bischoff...

15:23
Feinstein Institute for Medical Research Professors Betty Diamond, MD, and Peter K. Gregersen, MD, release data from their National Institutes of Health (NIH) research which reveals our cells' roles in rheumatoid arthritis and lupus.  ...

13:09
Key opinion leaders in the field of dermatology and hair loss published the first peer-reviewed article validating Nutrafol's approach to healthy hair growth. The article appeared in the November issue of the Journal of Drugs and Dermatology (JDD), a...

10:30
GSK presented today at the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices meeting that FLUARIX® QUADRIVALENT demonstrated 63.2% efficacy against moderate to severe influenza and 49.8% efficacy against...

08:35
NovoPath, Inc., makers of the NovoPathtm Laboratory Information System Software, announces that it will be a Benefactor Sponsor of the 23rd annual Executive War College (EWC) Conference on Laboratory and Pathology Management. The EWC, the nation's...

08:30
The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology and the ROS1ders announce the commencement of a global study to gain a deeper understanding of ROS1-positive cancer. The study is developing patient-derived xenografts (PDX)...

08:00
AbbVie , a global research and development-based biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. , announced that the Phase 3 ELARIS UF-I study (M12-815) of elagolix met its primary endpoint. Results from the first of two...

08:00
New real-world findings published in The Journal of Clinical Psychiatry expand on the growing evidence that people with treatment-resistant depression (TRD) bear a substantial economic burden tied to the disease. A person living with major depressive...

08:00
Regen BioPharma Inc. and has moved into the second stage of its previously-announced program to determine the three-dimensional structure of NR2F6 - with and without its proprietary small molecule drugs bound to it. The object of this...

07:00
Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced the presentation of preliminary data from its ongoing Phase 1 trials of its lead...

07:00
Sierra Oncology, Inc. , a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today announced it has been accepted to present preclinical data...

06:55
Evofem Biosciences, Inc., ("Evofem" or the "Company"), a biotechnology company developing innovative products to fill women's unmet healthcare needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation...

03:00
Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") announced today that it has entered into an exclusive worldwide license agreement with Catalent U.K. Swindon Zydis Limited, a subsidiary of Catalent, Inc. ("Catalent") to...


20 février 2018

16:05
Halozyme Therapeutics, Inc. , a biotechnology company developing novel oncology and drug-delivery therapies, today reported financial results and recent highlights for the fourth quarter and full-year ended December 31, 2017. "Building on a truly...

15:33
Axiom Foods, Inc. ("Axiom") has been awarded its first application patent for any rice protein ever, U.S. Patent No. 9,820,504 for its Oryzatein® rice protein; Axiom Foods is one of the largest makers of rice and pea protein ingredients. Allowed as...

13:58
Research funded by The ALS Association's Lawrence and Isabel Barnett Drug Development Program recently uncovered a new way to slow muscle paralysis in mice with ALS, findings that could point to new approaches to therapy for people with ALS....

13:30
Wize Pharma, Inc. , a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, today announced it has received Institutional Review Board (IRB) approval for the protocol of its planned Phase IV study. This...

11:30
Dr Anna Farago, oncologist from the Massachusetts General Hospital and principal investigator of the phase III ATLANTIS clinical trial, will present the potential of lurbinectedin in small-cell lung cancer along with the main clinical data on safety...

10:10
PharmaJet®, the maker of innovative, needle-free injection technology, today announced a global license agreement with Genexine, a leading biotherapeutics company headquartered in South Korea, for the development and commercialization of DNA vaccines...

10:00
Micromedic Technologies ("Micromedic"), announced successful results of a clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect® technology. The study successfully detected cells originated from the prostate...

09:17
Maxygen is pleased to announce the availability of the molecular breeding directed evolution platform to the biotechnology industry on a fee-for-service basis. This approach to improving protein function has broad applicability with particular...

09:00
Alcyone Lifesciences, Inc., a privately-held company focused on transforming disease modifying therapies for central nervous system (CNS) disorders today announced the separation and spin-off of its Hydrocephalus business. The new company, known as...

08:03
Catheter Precision Inc. announces the initiation of a pivotal clinical trial to assess the accuracy and safety of the VIVOtm (View Into Ventricular Onset) Non-Invasive Mapping System. The VIVO system is designed to provide pre-procedure guidance to...

1 2 3 4 5 6 7 8 9 10